TriangleCART (NCT07319676)
CART trial for B-cell Lymphoma Refractory (NCT07319676). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
CAR T cells against CD19 have changed the outlook for relapsed B-cell lymphoma. But after rounds of chemotherapy, a patient's T cells are worn down, and the engineered cells may fail to expand.
The idea: give the cells a receptor for a growth signal the body already makes.
At National University Hospital in Singapore, a patient's T cells receive the CD19 receptor together with a receptor for erythropoietin, the hormone that drives red blood cell production, so natural or supplemental erythropoietin can feed the T cells too. If the biopsy shows CD22 as well, a second CAR T product is added, making escape harder.
A safety study leading into phase two, ages ten to eighty. Michelle Poon leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.